McDermott Will & Schulte has advised Servier on the acquisition of BN104 from BioNova. Servier, an international, independent pharmaceutical group governed by a foundation, has completed...
Servier Acquires Menin Inhibitor BN104 from BioNova
Théradial Acquires TauroSept® Solution to Bolster Vascular Access Portfolio
McDermott Will & Schulte has advised Théradial. Théradial, a specialist in the distribution of medical devices and pharmaceuticals, has completed the acquisition of the TauroSept® solution,...
Orakl Oncology’s €11 Million Seed Funding Round
McDermott Will & Emery advised Orakl Oncology on the transaction. Orakl Oncology, a pioneering precision oncology company, closed a EUR 11 million seed funding round, led...
DiogenX’s EUR27.5 Million Serie A Fundraising
McDermott advised DiogenX in its fundraising. DiogenX, a biotechnology company specializing in the regeneration of beta cells that produce insulin for the treatment of diabetes, has...
Bill & Melinda Gates Foundation’s Equity Investment In Smart Immune
McDermott Will & Emery advised Smart Immune in this matter. The clinical-stage biotechnology company Smart Immune has secured a $5 million equity investment from the Bill...
ImCheck Therapeutics’ €96 Million Fundraising
Dentons Paris advised ImCheck Therapeutics on the transaction. McDermott Will & Emery advised McDermott advised EarlyBird and Andera Partners. Goodwin advised Bpifrance. Bpifrance, through its InnoBio...
DBV Technologies’ $194 Million Private Placement Financing
Gide advised Goldman Sachs and SVB Leerink LLC. McDermott Will & Emery advised DBV Technologies. DBV Technologies, a clinical-stage biopharmaceutical company, announced a private placement financing...
Aelis Farma’s IPO on Euronext Paris
IN BRIEF: McDermott Will & Emery, advised on the matter. McDermott Will & Emery advised AELIS FARMA with a team including Joseph Marx (Equity Capital Markets),...
Meiogenix’s $13 Million Series A Financing Round
McDermott Will & Emery advised Meiogenix on the round. Meiogenix announced the closing of a USD 13 million (EUR 11 million) Series A financing round led...
Corteria Pharmaceuticals’ €12 Million Financing Round
McDermott Will & Emery advised Corteria Pharmaceuticals on the deal. Corteria Pharmaceuticals, a French biotechnology company specializing in the development of interceptive therapies for heart failure...
Egle Therapeutics’ €40 Million Series A Funding Round
McDermott Will & Emery advised Egle Therapeutics on the deal. Gide advised the pool of investors, while Morgan, Lewis & Bockius advised Takeda Ventures. Egle Therapeutics,...